Trial record 2 of 253 for:    Lymphoma AND (women OR woman OR female)

Gonadal Toxicity in Women With Hodgkin Lymphoma (FertHD)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2009 by Gruppo Italiano Studio Linfomi.
Recruitment status was  Recruiting
Information provided by:
Gruppo Italiano Studio Linfomi Identifier:
First received: November 3, 2009
Last updated: November 11, 2009
Last verified: November 2009
The Gruppo Italiano Studio Linfomi has been collecting data on patients with Hodgkin Lymphoma (HL) since 1988. This archive represents a homogeneous series of consecutive patients with HL. The very long follow up and the availability of clinical and treatment data make it feasible to perform a study on the gonadal toxicity related to treatment for HL.

Hodgkin Lymphoma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Observational Retrospective Study to Evaluate the Incidence of the Gonadal Toxicity in Women of Reproductive Age With Hodgkin Lymphoma

Resource links provided by NLM:

Further study details as provided by Gruppo Italiano Studio Linfomi:

Primary Outcome Measures:
  • incidence of gonadal toxicity in terms of irreversible amenorrhea and infertility, in women of reproductive age with Hodgkin lymphoma treated with chemotherapy. [ Time Frame: from end of treatment until date of last contact/visit ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • role of a prophylactic treatment with oral contraceptives and GnRH analogs in preventing gonadal damage [ Time Frame: from end of treatment until date of last contact/visit ] [ Designated as safety issue: No ]

Estimated Enrollment: 150
Study Start Date: July 2009
women with hodgkin lymphoma treated with chemotherapy


Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Female patients with Hodgkin lymphoma diagnosed until 2007 in Italy will be considered eligible for this study. Cases will be identified from the archives of GISL.

Inclusion Criteria:

  • Female patients in complete remission after chemotherapy for Hodgkin lymphoma
  • Age ≥ 18 e < 40 years
  • Previous regular menstrual cycle
  • No previous or concomitant gynecological diseases affecting reproducing function
  • No other chemo-radiotherapy for other neoplasm
  • Written informed consent

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01008735

Contact: Antonella Montanini, BSc, PhD +39 059 4223284\

Gruppo Italiano Studio Linfomi Recruiting
Modena, Italy
Contact: Antonella Montanini, BSc, PhD    +39 059 4223284   
Principal Investigator: Massimo Federico, MD         
Sponsors and Collaborators
Gruppo Italiano Studio Linfomi
Study Chair: Francesco Angrilli, MD GISL
Study Chair: Simona Falorio, MD GISL
Study Chair: Massimo Federico, MD GISL
  More Information

No publications provided

Responsible Party: Massimo Federico, Gruppo Italiano Studio Linfomi Identifier: NCT01008735     History of Changes
Other Study ID Numbers: FertHD 
Study First Received: November 3, 2009
Last Updated: November 11, 2009
Health Authority: Italy: Ethics Committee

Additional relevant MeSH terms:
Hodgkin Disease
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type processed this record on February 08, 2016